Clinical and Experimental Hypertension, 30:767–775, 2008
ISSN: 1064-1963 print / 1525-6006 online
DOI: 10.1080/10641960802563568
Amenta F, Traini E. Tomassoni D, Mignini F Pharmacokinetics of Different Formulations of Tioctic (Alpha-Lipoic) Acid in Healthy Volunteers
This article was originally published with an incorrect indication of formulations of alpha-lipoic-acid used throughout the manuscript.
Tiocronal 600 HR should be Tiocronal 300 HR two tablets (600 mg)
Tiobec 600 retard should be Tiobec 200 retard three tablets (600 mg)
The Subjects and methods section, heading Subjects, lines 3–6, should be:
Byodinoral 600 QR, 600 mg tablets (MDM S.p.A., Monza, Italy);
Tiocronal 300 HR, 300 mg tablets (Fidia Farmaceutici S.p.A., Abano Terme, Italy), dose administered two tablets, for a total of 600 mg.
Tiobec 200 mg retard tablets (Laborest Italia S.p.A., Nerviano, Italy), dose administered three tablets for a total of 600 mg; and heading Treatment, lines 4–5, should be:
Treatment consisted of the administration of one tablet of Byodinoral 600 QR, three tablets of Tiobec retard 200 or two tablets Tiocronal 300 HR to fasting subjects at 08:00 a.m.
The above incorrect indication could be misleading primarily for Laborest Italia S.p.A., as a Tiobec 600 mg tablets was never produced or marketed by this firm. The authors apologize for the mistake due to problems in editing the final version of the manuscript and for any inconvenience this may have caused. Of course, all the concepts and consequences developed in the manuscript cannot be referred to Tiocronal 600 HR or Tiobec 600 retard, but to the 600 mg dosage of formulations used.